A diverse repertoire of T cells directed against a small number of cancer-specific targets is key to the success of immune checkpoint blockade in patients with metastatic melanoma, a finding that could shape the design of neoantigen-specific vaccines and adoptive cell therapies.

©2023 American Association for Cancer Research
2023
American Association for Cancer Research
You do not currently have access to this content.